AVAVA, Inc. — SEC Form D Filing

AVAVA, Inc. filed an SEC Form D on March 4, 2026, reporting $19.61M raised in Health Care.

Form D filing details

Filing
SEC Form D
Filing date
March 4, 2026
Amount reported
$19.61M
Round stage
Seed
Industry
Health Care
Website
https://avavaskin.com/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many individuals struggle with skin issues that require effective and precise treatments. Providers need advanced tools to meet diverse patient skincare needs.

Solution

AVAVA offers advanced skin treatments using Focal Point Technology that deliver personalized solutions for various skin types, enhancing patient care and results.

Why now

There is a growing demand for personalized and effective skin treatments as awareness of skincare continues to rise.

Verdict

Investors backed AVAVA because it addressed a compelling gap in the skincare market, where personalized treatment is increasingly in demand, not because traditional solutions were working well. They were betting that the technology would not only perform reliably but also secure adoption among medical providers who prioritize outcomes. However, the narrative’s limited upside comes from potential reliance on technology and training, which may restrict scalability if these elements do not meet expectations.

Source: SEC EDGAR Form D filing